Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pharma companies to...

    Pharma companies to see moderation in growth in US market: Icra

    Written by savita thakur thakur Published On 2016-06-05T16:29:15+05:30  |  Updated On 5 Jun 2016 4:29 PM IST
    Pharma companies to see moderation in growth in US market: Icra

    The Indian drug firms have registered strong growth over last decade driven mainly by the US market.


    NEW DELHI: Indian drug industry will see moderation in growth due to slowing of business in the US market with reduction in the number of large size drugs going off patent, increased competition and generic adoption reaching saturation levels, Icra said today.


    The Indian drug firms have registered strong growth over last decade driven mainly by the US market.


    "However growth from the US has come down to 15 per cent in FY2016 and going forward the growth momentum is likely to face further pressure," rating agency Icra said in a statement.

    Increased regulatory scrutiny as reflected in increased issuance of warning letters/import alerts and consolidation of supply chain in the US market resulting in pricing pressures will have an impact on profitability of Indian pharmaceutical companies, it said.

    However, in spite of these ongoing challenges, several Indian pharma companies are increasing their R&D spend, targeting pipeline of specialty drugs, niche molecules and complex therapies, Icra noted.

    Commenting on the domestic market, it said continued regulatory interventions are expected to put some pressure in near term though long term growth prospects for domestic drug market remain healthy given increasing penetration, accessibility and continued new launches.

    "The key concern for domestic market relates to continued regulatory interventions in form of expanded list of National List of Essential Medicines (NLEM) along with recent ban on 344 fixed dose combination (FDC) drugs," it said.
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok